ZIF drug-loaded coating on surface of magnesium matrix and preparation method of ZIF drug-loaded coating
By synthesizing ZIF drug-loading coatings in situ on the surface of magnesium alloy, the challenges of traditional coatings in long-term stability and biocompatibility are solved, and the corrosion resistance and antibacterial properties of magnesium alloys are improved, achieving high purity and uniformity The effect of coverage.
Patent Information
- Application Number
- CN202411132684.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
AI Technical Summary
Traditional magnesium alloy surface drug-loaded coatings have challenges in long-term stability and biocompatibility, and lack antibacterial properties, resulting in the coating being easily peeled off or bacterial adhesion, affecting its function.
ZIF (zeolite-like imidazole skeleton MOF) is used for in-situ synthesis on the surface of magnesium alloy. By mixing Zn(NO3)2·6H2O and imidazole ligand with a drug solution, immersing it in-situ synthesis in magnesium alloy matrix to form a high purity ZIF drug-loaded coating enhances the bond strength of the coating to the matrix and imparts antibacterial properties.
It significantly improves the biocompatibility and corrosion resistance of magnesium alloys, enhances the adhesion between the coating and the substrate, avoids the introduction of external impurities, achieves uniform coverage and precise control of drug release, and enhances antibacterial performance.
Smart Images

Figure HDA0004998401460000011 
Figure HDA0004998401460000012 
Figure HDA0004998401460000021
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of magnesium alloy surface treatment, and in particular relates to a ZIF drug-loaded coating on the surface of a magnesium substrate and a preparation method thereof. Background Art
[0002] Magnesium and magnesium alloys have been widely studied and applied in the fields of biomedicine and engineering structures due to their excellent physical and chemical properties, such as low density, high strength and good biocompatibility. However, magnesium and magnesium alloys have problems such as fast corrosion rate and biocompatibility. In order to overcome these problems, researchers have proposed various surface modification strategies. Among them, drug-loaded coatings are used to control drug release and improve the biocompatibility and corrosion resistance of the substrate by forming a covering layer containing active substances (such as drugs, growth factors, etc.) on the surface of the material. Traditional drug-loaded coatings usually use materials such as polymers, but these materials cannot fully meet the special needs of magnesium alloys, especially in terms of long-term stability and biocompatibility. There are challenges, and the degradation rate of many polymer coatings is inconsistent with that of magnesium alloys, which will cause the coating to fail prematurely or the magnesium alloy to be exposed to the physiological environment, affecting its function. At the same time, polymer coatings lack antibacterial properties and cannot effectively prevent bacteria from attaching and growing on the surface of the coating, increasing the risk of infection.
[0003] Metal-organic framework materials (MOFs), as a new type of functional material, have shown extensive application potential in various fields. MOFs are composed of metal ions and organic ligands connected by coordination bonds, and have the advantages of high porosity, uniform and controllable pore size, and high reactivity. In recent years, the research on MOFs has not only been limited to traditional industrial and environmental applications, but has also expanded to the biomedical field, showing unique advantages in drug delivery and biomaterial modification. However, most methods for preparing MOF coatings on magnesium and magnesium alloy surfaces are to construct chemical conversion films, electrodeposition, or incorporate MOF into polymers. However, the adhesion between polymer coatings and metal substrates is weak, and the coatings are prone to peeling or cracking when subjected to mechanical stress, temperature changes, or humid environments. In addition, traditional methods for preparing MOF coatings have problems such as difficulty in controlling coating thickness and uniformity, poor adhesion between coatings and substrates, complex operations, and long time consumption. Summary of the invention
[0004] In order to solve the above problems, the present invention provides a ZIF drug coating on the surface of a magnesium substrate and a preparation method thereof. ZIF (zeolite imidazole framework MOF) can more accurately control drug release. In addition, the ZIF material also has abundant reaction sites, which helps to enhance the bonding strength between the coating and the substrate. The method of the present invention realizes the in-situ growth of the ZIF coating on the surface of the magnesium alloy. The in-situ synthesis of the ZIF coating can avoid the introduction of external impurities, prepare a ZIF coating with higher purity, and significantly improve the biocompatibility and corrosion resistance of the magnesium alloy.
[0005] The present invention is achieved through the following technical solutions
[0006] The present invention provides a ZIF coating on the surface of a magnesium substrate and a preparation method thereof, the method comprising the following steps:
[0007] (1) Pre-treating magnesium or magnesium alloy, and using the pre-treated magnesium or magnesium alloy as a matrix material for later use;
[0008] (2) a solution containing Zn(NO3)2·6H2O is used as solution I, a solution containing imidazole ligand and drug is used as solution II, and solution I and solution II are mixed evenly to obtain a synthetic solution;
[0009] (3) Immerse the pure magnesium or magnesium alloy substrate material treated in step (1) into the synthesis solution of step (2) and perform in-situ synthesis at 60-110° C. After the reaction is completed, take out the sample, wash it, and dry it in turn to obtain a ZIF drug-loaded coating on the surface of the magnesium substrate.
[0010] Furthermore, the magnesium matrix described in step (1) can be high-purity magnesium, Mg-Zn series, Mg-Re series or Mg-Al series alloy. Furthermore, the pretreatment described in step (1) includes polishing with SiC sandpaper #100, #200, #400, #600, #800 and #1000 in sequence, polishing with 0.25μm diamond polishing agent, ultrasonic cleaning in anhydrous ethanol, and then drying with cold air. Furthermore, the concentration of Zn(NO3)2·6H2O in the solution I described in step (2) is 5 to 20mM.
[0011] Furthermore, in step (2), the concentration of the imidazole ligand is 30-300 mM, and the concentration of the drug is 0.5-20 mM.
[0012] Further, the imidazole ligand includes 2-ethylimidazole, 2-methylimidazole, benzimidazole, and imidazole;
[0013] and / or, the drug may be a pro-endothelialization, anti-inflammatory or antibacterial drug;
[0014] And / or, the drug may be rapamycin, paclitaxel or vancomycin.
[0015] Furthermore, the volume ratio of solution I to solution II in the synthetic solution is preferably 1:1.
[0016] Furthermore, the solvent used in the solution I and solution II in step (2) can be N,N,-dimethylformamide, isopropanol or water.
[0017] Furthermore, the solvent used in the solution I and solution II in step (2) is preferably N,N-dimethylformamide.
[0018] Furthermore, the in-situ synthesis time is 2 to 6 hours.
[0019] Furthermore, the reagents used in the washing process are N,N,-dimethylformamide and anhydrous ethanol.
[0020] The present invention also provides a ZIF drug-loaded coating on the surface of a magnesium substrate prepared by the above method. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is the SEM morphology of the coating prepared in Example 1;
[0022] Figure 2 is the XRD pattern of the coating prepared in Example 1;
[0023] Figure 3 FT-IR image of the coating prepared in Example 1;
[0024] Figure 4 The fluorescence images of cytoskeleton staining of endothelial cells cultured with the extract of the bare substrate (a) and the coating sample (b) for 72 hours in Example 1;
[0025] Figure 5 The results of the plate coating experiment of Staphylococcus aureus on the bare substrate (a) and the coating sample (b) in Example 1;
[0026] Figure 6 is the SEM morphology of the coating in Example 2;
[0027] Figure 7 is the SEM morphology of the coating in Example 3;
[0028] Figure 8 This is the SEM morphology of the coating in Example 4.
[0029] The present invention has the following positive beneficial effects
[0030] The present invention realizes the in-situ growth of the ZIF coating on the surface of the magnesium alloy. This "in-situ synthesis" method simplifies the preparation process. Through this method, the coating forms a chemical bond with the magnesium alloy substrate, which significantly improves the bonding strength between the coating and the metal substrate. The ZIF coating is directly generated on the metal surface, has strong adhesion, and is more tightly bonded to the substrate; at the same time, the method also improves the corrosion resistance of the substrate, and gives the coating antibacterial properties and the function of controlling drug release.
[0031] The ZIF coating completely and evenly covers the metal surface, avoiding the problem of uneven coating. The thickness and composition of the coating can also be precisely controlled during the preparation process, thereby improving the controllability of the coating. In-situ synthesis of ZIF coatings can avoid the introduction of external impurities, prepare ZIF coatings with higher purity, and significantly improve the biocompatibility and corrosion resistance of magnesium alloys.
[0032] ZIF is responsive to weakly acidic environments associated with various diseases such as tumors and is an ideal carrier for controlling drug transport and release. DETAILED DESCRIPTION
[0033] The present invention is described in more detail below through specific implementation modes to facilitate understanding of the technical solution of the present invention, but is not intended to limit the protection scope of the present invention.
[0034] Example 1
[0035] A method for preparing a ZIF-14 drug-loaded coating on a magnesium substrate surface comprises the following steps:
[0036] (1) The extruded Mg-2Zn-0.46Y-0.5Nd (wt.%) sheet (Φ10*4 mm) was polished with SiC sandpaper #100, #200, #400, #600, #800 and #1000 in sequence, and then polished with 0.25 μm diamond polishing agent. After polishing, it was placed in anhydrous ethanol for ultrasonic cleaning for 10 min to remove oil stains, etc., and then taken out and dried with cold air;
[0037] (2) dissolving Zn(NO3)2·6H2O in N,N,-dimethylformamide to prepare solution I, and dissolving rapamycin and 2-ethylimidazole in dimethylformamide to prepare solution II;
[0038] The concentration of Zn(NO3)2·6H2O in the obtained solution I was 10 mM; the concentration of 2-ethylimidazole in the obtained solution II was 50 mM, and the content of rapamycin was 6 mM;
[0039] Take 5 mL of solution I and solution II and mix them to obtain a synthetic solution;
[0040] (3) immersing the Mg-2Zn-0.46Y-0.5Nd sample treated in step (1) into the synthetic solution of step (2), and heating it in a vacuum drying oven at 60° C. for 2 h;
[0041] (4) After heating in step (3), the sample is taken out, rinsed with N,N,-dimethylformamide and anhydrous ethanol in sequence, and dried naturally to obtain a ZIF-14 drug-loaded (rapamycin) coating on the surface of a magnesium substrate.
[0042] The coating prepared in Example 1 was tested, and the results were as follows: Figure 1 , Figure 2 and Figure 3 shown.
[0043] The coating morphology is Figure 1 As shown, crystal formation with clear edges can be observed on the metal surface, and ZIF-14 crystals completely and evenly cover the entire surface densely;
[0044] Chemical composition analysis of the coating surface. Figure 2 The XRD patterns of the coating and the corresponding ZIF-14 powder. In the coating pattern, the peaks at 8°, 13° and 18° correspond to the (112), (004) and (125) crystal planes of ZIF-14, respectively, proving that the crystal structure of the coating surface is similar to that of ZIF-14.
[0045] Analyze the functional groups on the coating surface. Figure 3 This is the infrared spectrum of the coating, spectrum 419cm -1 The left and right sides correspond to the vibration peak of Zn-N; 741cm -1 and 954cm -1 It corresponds to the bending and stretching vibration peaks of CH on the imidazole ring; 2963cm -1 The 1050 cm-1 corresponds to the stretching vibration of CH on the methyl group; -1 and 1140cm -1 Corresponding to the vibration peak of CN on the imidazole ring; 1045cm -1 Corresponding to the stretching vibration peak of C=C; both XRD spectrum and infrared spectrum prove the successful preparation of ZIF-14 crystals.
[0046] The following experiment was conducted using the ZIF-14 drug-loaded (rapamycin) coating on the magnesium substrate surface prepared in Example 1:
[0047] Before the cell experiment, the bottom and front surfaces of the bare substrate (control) and the coated sample (sample prepared in Example 1) were sterilized with ultraviolet light for 30 minutes each. The vascular endothelial cells were cultured with RPMI-1640 complete medium. First, the sterilized samples were placed in a sterile well plate, and then 0.7 mL of RPMI-1640 complete medium was added to each well plate. The well plate was placed in a constant temperature incubator at 37°C and 5% CO2 and soaked for 24 hours. The supernatant was aspirated, and then 10% serum (FBS) and 1% penicillin-streptomycin were added to the supernatant. The vascular endothelial cells were cultured at 1×10 4The cells were inoculated at a density of 100 cells / mL in a 24-well plate with a cell slide, and then placed in a CO2 incubator (37°C) for 72 hours, with the extract replaced every 24 hours; after the culture was completed, the waste liquid was aspirated, and the cells were fixed with a 4% paraformaldehyde solution for 40 minutes after washing with PBS; after fixation, the cells were washed with PBS; then, 5% BSA (bovine serum albumin) was used to block the cells for 40 minutes, and after blocking, PBS was used to wash; then, 80 μL of phalloidin solution was added for staining, and PBS was used to wash after 40 minutes; then, 80 μL of DAPI was added to react in the dark for 5 minutes, and then washed with PBS; finally, a confocal super-resolution microscope was used to observe and take pictures, and the results are shown in the following figure. Figure 4 Compared with the bare substrate, the cells on the drug-loaded coating were more spread out and the amount of cell adhesion increased, proving that the drug-loaded coating was beneficial to the proliferation of endothelial cells.
[0048] The ZIF-14 drug-loaded (rapamycin) coating on the surface of the magnesium substrate prepared in Example 1 was used to carry out an antibacterial test on Staphylococcus aureus, and the experiment was as follows:
[0049] Dilute the bacterial solution to 5×10 7 CFU / mL for later use. Then, place the bare substrate (comparison) and the coated sample (sample prepared in Example 1) that have been sterilized by ultraviolet light in a 24-well plate, and take 60 μL of the diluted bacterial solution to inoculate the surface of the sample, and place these samples inoculated with the bacterial solution in a constant temperature incubator at 37°C for static culture for 24 hours. After completing the surface culture, place the sample with bacteria in a centrifuge tube containing 4 mL of 0.9% NaCl solution, use an oscillator to shake off the bacteria on the surface of the sample, and draw 100 μL of bacterial solution from it and drop it on the LB solid agar medium. Use a push rod to evenly spread the bacterial solution on the agar plate to ensure that the bacteria are evenly distributed, and place it in a constant temperature incubator for culture for 18 hours. After the culture is completed, take a picture with a digital camera. The results are as follows Figure 5 The number of colonies on the coated samples was less, proving that the coating enhanced the antibacterial activity of magnesium alloy against Staphylococcus aureus.
[0050] Example 2
[0051] A method for preparing a ZIF-8 drug coating on a magnesium substrate surface comprises the following steps:
[0052] (1) The extruded Mg-2Zn-0.46Y-0.5Nd (wt.%) sheet (Φ10*4 mm) was polished with SiC sandpaper #100, #200, #400, #600, #800 and #1000 in sequence, and then polished with 0.25 μm diamond polishing agent. After polishing, it was placed in anhydrous ethanol for ultrasonic cleaning for 10 min to remove oil stains, etc., and then taken out and dried with cold air;
[0053] (2) dissolving Zn(NO3)2·6H2O in N,N,-dimethylformamide to prepare solution I, and dissolving rapamycin and 2-methylimidazole in dimethylformamide to prepare solution II;
[0054] The concentration of Zn(NO3)2·6H2O in solution I was 10mM; the concentration of 2-methylimidazole in solution II was 22mM, and the content of rapamycin was 6mM;
[0055] Take 5 mL of solution I and solution II and mix them to obtain a synthetic solution;
[0056] (3) immersing the Mg-2Zn-0.46Y-0.5Nd sample treated in step (1) into the synthetic solution of step (2), and heating it in a vacuum drying oven at 110° C. for 2 h;
[0057] (4) After the end, the sample is taken out, washed with N,N,-dimethylformamide and anhydrous ethanol in sequence, and dried naturally to obtain a ZIF-8 drug-loaded (rapamycin) coating on the surface of the magnesium substrate.
[0058] The coating prepared in Example 2 was tested and the morphology was as follows Figure 6 As shown, it can be observed that ZIF-8 crystals are evenly and densely spread over the entire surface on the metal surface.
[0059] Example 3
[0060] A method for preparing a ZIF-62 drug-loaded coating on a magnesium substrate surface comprises the following steps:
[0061] (1) The extruded Mg-2Zn-0.46Y-0.5Nd (wt.%) sheet (Φ10*4 mm) was polished with SiC sandpaper #100, #200, #400, #600, #800 and #1000 in sequence, and then polished with 0.25 μm diamond polishing agent. After polishing, it was placed in anhydrous ethanol for ultrasonic cleaning for 10 min to remove oil stains, etc., and then taken out and dried with cold air;
[0062] (2) dissolving Zn(NO3)2·6H2O in N,N,-dimethylformamide to prepare solution I, and dissolving paclitaxel, imidazole and benzimidazole in N,N,-dimethylformamide to prepare solution II;
[0063] The concentration of Zn(NO3)2·6H2O in solution I was 20 mM; the concentration of imidazole in solution II was 20 mM, the concentration of benzimidazole was 27 mM, and the content of paclitaxel was 6 mM;
[0064] Take 5 mL of solution I and solution II and mix them to obtain a synthetic solution;
[0065] (3) immersing the Mg-2Zn-0.46Y-0.5Nd sample treated in step (1) into the synthetic solution of step (2), and heating it in a vacuum drying oven at 110° C. for 2 h;
[0066] (4) After the end, the sample is taken out, washed with N,N,-dimethylformamide and anhydrous ethanol in sequence, and dried naturally to obtain a ZIF-62 drug-loaded (paclitaxel) coating on the surface of the magnesium substrate.
[0067] The coating prepared in Example 3 was tested and the morphology was as follows: Figure 7 As shown, it can be observed on the metal surface that ZIF-62 crystals are evenly and densely spread over the entire surface.
[0068] Example 4
[0069] A method for preparing a ZIF-14 drug-loaded coating on a magnesium substrate surface comprises the following steps:
[0070] (1) The extruded Mg-2.1Zn-0.22Ca (wt.%) sheet (Φ10*4 mm) was polished with SiC sandpaper #100, #200, #400, #600, #800 and #1000 in sequence, and then polished with 0.25 μm diamond polishing agent. After polishing, it was ultrasonically cleaned in anhydrous ethanol for 10 min to remove oil stains, etc., and then taken out and dried with cold air;
[0071] (2) dissolving Zn(NO3)2·6H2O in N,N,-dimethylformamide to prepare solution I, and dissolving vancomycin and 2-ethylimidazole in dimethylformamide to prepare solution II;
[0072] The concentration of Zn(NO3)2·6H2O in solution I was 40 mM; the concentration of 2-ethylimidazole in solution II was 200 mM, and the content of vancomycin was 6 mM;
[0073] Take 5 mL of solution I and solution II and mix them to obtain a synthetic solution;
[0074] (3) immersing the Mg-2.1Zn-0.22Ca sample treated in step (1) into the synthetic solution of step (2), and heating it in a vacuum drying oven at 60° C. for 2 h;
[0075] (4) After the end, the sample is taken out, washed with N,N,-dimethylformamide and anhydrous ethanol in sequence, and dried naturally to obtain a ZIF-14 drug-loaded (vancomycin) coating on the surface of the magnesium substrate.
[0076] The coating prepared in Example 4 was tested and the morphology was as follows Figure 8 As shown, it can be observed that ZIF-14 crystals are evenly and densely spread over the entire surface on the metal surface.
Claims
1. A method for preparing a ZIF drug-loaded coating on a magnesium substrate, the method comprising the following steps: (1) Pre-treating magnesium or magnesium alloy, and using the pre-treated magnesium or magnesium alloy as a matrix material for later use; (2) a solution containing Zn(NO3)2·6H2O is used as solution I, a solution containing imidazole ligand and drug is used as solution II, and solution I and solution II are mixed evenly to obtain a synthetic solution; (3) Immerse the pure magnesium or magnesium alloy substrate material treated in step (1) into the synthesis solution of step (2) and perform in-situ synthesis at 60-110° C. After the reaction is completed, take out the sample, wash it, and dry it in turn to obtain a ZIF drug-loaded coating on the surface of the magnesium substrate.
2. The preparation method according to claim 1, characterized in that: The concentration of Zn(NO3)2·6H2O in the solution I of step (2) is 5 to 20 mM.
3. The preparation method according to claim 1, characterized in that: In step (2), the concentration of the imidazole ligand is 30-300 mM, and the concentration of the drug is 0.5-20 mM.
4. The preparation method according to claim 3, characterized in that: The imidazole ligands include 2-ethylimidazole, 2-methylimidazole, benzimidazole, and imidazole.
5. The preparation method according to claim 1, characterized in that: The time of the in-situ synthesis in step (3) is 2 to 6 hours.
6. The preparation method according to any one of claims 1 to 5, characterized in that: The drug in step (2) may be an endothelial-promoting, anti-inflammatory or antibacterial drug; And / or, the drug may be rapamycin, paclitaxel or vancomycin.
7. The preparation method according to any one of claims 1 to 5, characterized in that: The volume ratio of solution I to solution II in the synthetic solution described in step (2) is preferably 1:
1.
8. The preparation method according to any one of claims 1 to 5, characterized in that: The pretreatment described in step (1) includes polishing with SiC sandpaper #100, #200, #400, #600, #800 and #1000 in sequence, polishing with 0.25μm diamond polishing agent, ultrasonic cleaning in anhydrous ethanol, and then drying with cold air.
9. The preparation method according to any one of claims 1 to 5, characterized in that: The solvent used for solution I and solution II in step (2) can be N,N,-dimethylformamide, isopropanol or water.
10. The ZIF drug-loaded coating on the surface of a magnesium substrate prepared by the preparation method according to any one of claims 1 to 9.
Citation Information
Cited By
Porous frame coating as well as preparation method and application thereof
CN121466384A
